March ⁠19 (Reuters) - ⁠The U.S. ⁠Food and ​Drug ‌Administration approved ‌GSK's ⁠drug for ⁠severe relentless itching ​caused ...

Linerixibat approved for cholestatic itch in primary biliary cholangitis ...

GSK (GSK) stock is in focus as the company wins FDA nod for Lynavoy, the first U.S. treatment for cholestatic pruritus in ...

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.

GSK said on Thursday that the US Food and Drug Administration has approved its drug ‘Lynavoy’, or linerixibat, for the ...

The US regulator confirmed approval of IBAT inhibitor linerixibat, under the Lynavoy trade name, as a treatment for cholestatic pruritus in PBC on 17th March. PBC is a chronic, progressive autoimmune ...

Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. | Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary ...

The double-blind, randomised, placebo-controlled trial will assess the efficacy and safety of Livmarli in both children and ...

The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader ...

Peking University, October 30, 2024: Addressing the challenge of cholestatic itch, the scientific community has been pursuing innovative solutions. Recently, researchers from Peking University, led by ...

For the best experience, please enable JavaScript in your browser settings. UK: A tormented toddler's rare liver disease causes him to itch so much he deliberately ...

Cirrhosis can cause scar tissue to gradually replace healthy liver cells. In time, this can affect liver function and lead to hair, skin, and nail symptoms such as rashes and discoloration. Cirrhosis ...